Treating metabolic dysfunction-associated steatotic liver disease with precision medicine
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a complex condition influenced by genetic, metabolic, and environmental factors, often coexisting with type 2 diabetes, cardiovascular disease, and obesity.
The absence of approved pharmacological treatments, disease heterogeneity, lack of reliable noninvasive biomarkers, inadequate preclinical models, and socioeconomic barriers hinder personalized approaches.
Integrating digital health tools, behavioral strategies, and social determinants of health can improve adherence and treatment effectiveness.
A precision medicine framework, incorporating targeted therapies and interdisciplinary collaboration, is essential for advancing MASLD management.
https://www.cell.com/trends/endocrinology-metabolism/fulltext/S1043-2760(25)00052-9
